Pharmacy World and Science

, Volume 18, Issue 1, pp 16–19 | Cite as

Alglucerase (CeredaseTM)

  • E. H. H. Wiltink
  • C. E. M. Hollak
Drug Profile


Adverse effects Alglucerase Dosage Drug therapy Gaucher disease Pharmacokinetics Pharmacology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barranger JA, Ginns El. Glucosylceramide lipodoses: Gaucher disease. In: Scriver CRBA, Sly WS, Valle D, ed. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989;1677–98.Google Scholar
  2. 2.
    Hollak CEM, Aerts JMFG, Goudsmit R. De ziekte van Gaucher; nieuwe ontwikkelingen in de behandeling van lysosomale stapelingsziekten [Gaucher disease; new developments in the treatment of lysosomal storage diseases]. Ned Tijdschr Geneesk 1991;135(46):2162–4.Google Scholar
  3. 3.
    Barton NW, Furbisch FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous administration of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:1913–6.Google Scholar
  4. 4.
    Barton NW, Brady RO, Dambrosia JM, di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency — macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464–70.Google Scholar
  5. 5.
    Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, et al. A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992;327:1632–6.Google Scholar
  6. 6.
    Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, et al. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 1994;97:3–13.Google Scholar
  7. 7.
    Zimran A, Hadas-Halpern I, Zevin S, Levy-Lahad E, Abrahamov A. Low dose high frequency enzyme replacement therapy for very young children with Gaucher disease. Br J Haematol 1993;85:783–6.Google Scholar
  8. 8.
    Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82(2):408–16.Google Scholar
  9. 9.
    Hollak CEM, Aerts JMFG, Goudsmit R, Phoa SSKS, Ek M, van Weely S, et al. Individualized low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 1995;345:1474–8.Google Scholar
  10. 10.
    Zimran A, Hollak CEM, Abrahamov A, van Oers MHJ, Kelly M, Beutler E. Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993;82(4):1107–9.Google Scholar
  11. 11.
    van Weely S, van Leeuwen MB, Jansen IDC, de Bruyn MAC, Brouwer-Kelder EM, Schram AW, et al. Clinical phenotype in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochem Biophys Acta 1991;1096:301–11.Google Scholar
  12. 12.
    Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33–9.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • E. H. H. Wiltink
    • 1
  • C. E. M. Hollak
    • 2
  1. 1.Department of Clinical PharmacySt Antonius HospitalNieuwegeinthe Netherlands
  2. 2.Department of Internal MedicineAcademic Medical CentreAmsterdamthe Netherlands

Personalised recommendations